25 XP   0   0   10

Inhibikase Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Inhibikase together

PenkeI guess you are interested in Inhibikase Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Inhibikase Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Inhibikase Therapeutics Inc

I send you an email if I find something interesting about Inhibikase Therapeutics Inc.

Quick analysis of Inhibikase (30 sec.)










What can you expect buying and holding a share of Inhibikase? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.43
Expected worth in 1 year
$0.79
How sure are you?
15.8%

+ What do you gain per year?

Total Gains per Share
$-1.64
Return On Investment
-71.1%

For what price can you sell your share?

Current Price per Share
$2.30
Expected price per share
$1.45 - $3.12
How sure are you?
50%

1. Valuation of Inhibikase (5 min.)




Live pricePrice per Share (EOD)

$2.30

Intrinsic Value Per Share

$-50.63 - $-59.88

Total Value Per Share

$-48.20 - $-57.45

2. Growth of Inhibikase (5 min.)




Is Inhibikase growing?

Current yearPrevious yearGrowGrow %
How rich?$15m$31.7m-$11.5m-57.2%

How much money is Inhibikase making?

Current yearPrevious yearGrowGrow %
Making money-$4.6m-$4.6m$58.9k1.3%
Net Profit Margin-5,079.8%-100,344.5%--

How much money comes from the company's main activities?

3. Financial Health of Inhibikase (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#636 / 1031

Most Revenue
#628 / 1031

Most Profit
#441 / 1031

Most Efficient
#921 / 1031

What can you expect buying and holding a share of Inhibikase? (5 min.)

Welcome investor! Inhibikase's management wants to use your money to grow the business. In return you get a share of Inhibikase.

What can you expect buying and holding a share of Inhibikase?

First you should know what it really means to hold a share of Inhibikase. And how you can make/lose money.

Speculation

The Price per Share of Inhibikase is $2.3. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Inhibikase.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Inhibikase, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.43. Based on the TTM, the Book Value Change Per Share is $-0.41 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.73 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Inhibikase.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.74-32.3%-0.78-34.0%-0.76-33.1%-0.48-20.9%-0.48-20.9%
Usd Book Value Change Per Share-0.72-31.3%-0.41-17.8%-0.73-31.7%0.135.6%0.135.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.72-31.3%-0.41-17.8%-0.73-31.7%0.135.6%0.135.6%
Usd Price Per Share1.39-1.54-1.15-1.49-1.49-
Price to Earnings Ratio-0.47--0.46--0.38--0.95--0.95-
Price-to-Total Gains Ratio-1.93--1.39--1.58--2.74--2.74-
Price to Book Ratio0.57-0.51-0.22-0.66-0.66-
Price-to-Total Gains Ratio-1.93--1.39--1.58--2.74--2.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share2.3
Number of shares434
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.410.13
Usd Total Gains Per Share-0.410.13
Gains per Quarter (434 shares)-177.4655.45
Gains per Year (434 shares)-709.85221.81
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-710-7200222212
20-1420-14300444434
30-2130-21400665656
40-2839-28500887878
50-3549-3560011091100
60-4259-4270013311322
70-4969-4980015531544
80-5679-5690017741766
90-6389-6400019961988
100-7099-7110022182210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.019.00.00.0%0.019.00.00.0%0.019.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%3.013.03.015.8%3.013.03.015.8%3.013.03.015.8%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.019.00.0%0.00.019.00.0%0.00.019.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%3.013.03.015.8%3.013.03.015.8%3.013.03.015.8%

Fundamentals of Inhibikase

About Inhibikase Therapeutics Inc

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Fundamental data was last updated by Penke on 2024-03-20 20:55:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Inhibikase Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Inhibikase earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Inhibikase to the Biotechnology industry mean.
  • A Net Profit Margin of -5,775.1% means that $-57.75 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Inhibikase Therapeutics Inc:

  • The MRQ is -5,775.1%. The company is making a huge loss. -2
  • The TTM is -5,079.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-5,775.1%TTM-5,079.8%-695.3%
TTM-5,079.8%YOY-100,344.5%+95,264.7%
TTM-5,079.8%5Y-22,559.9%+17,480.0%
5Y-22,559.9%10Y-22,559.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,775.1%-171.8%-5,603.3%
TTM-5,079.8%-205.8%-4,874.0%
YOY-100,344.5%-262.1%-100,082.4%
5Y-22,559.9%-455.6%-22,104.3%
10Y-22,559.9%-589.0%-21,970.9%
1.1.2. Return on Assets

Shows how efficient Inhibikase is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Inhibikase to the Biotechnology industry mean.
  • -25.7% Return on Assets means that Inhibikase generated $-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Inhibikase Therapeutics Inc:

  • The MRQ is -25.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -20.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-25.7%TTM-20.6%-5.1%
TTM-20.6%YOY-13.3%-7.3%
TTM-20.6%5Y-153.7%+133.1%
5Y-153.7%10Y-153.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-25.7%-12.5%-13.2%
TTM-20.6%-12.2%-8.4%
YOY-13.3%-11.2%-2.1%
5Y-153.7%-13.4%-140.3%
10Y-153.7%-14.7%-139.0%
1.1.3. Return on Equity

Shows how efficient Inhibikase is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Inhibikase to the Biotechnology industry mean.
  • -30.6% Return on Equity means Inhibikase generated $-0.31 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Inhibikase Therapeutics Inc:

  • The MRQ is -30.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -24.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-30.6%TTM-24.0%-6.6%
TTM-24.0%YOY-15.1%-8.9%
TTM-24.0%5Y-11.4%-12.5%
5Y-11.4%10Y-11.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-30.6%-15.8%-14.8%
TTM-24.0%-15.7%-8.3%
YOY-15.1%-13.9%-1.2%
5Y-11.4%-18.3%+6.9%
10Y-11.4%-19.2%+7.8%

1.2. Operating Efficiency of Inhibikase Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Inhibikase is operating .

  • Measures how much profit Inhibikase makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Inhibikase to the Biotechnology industry mean.
  • An Operating Margin of -5,993.4% means the company generated $-59.93  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Inhibikase Therapeutics Inc:

  • The MRQ is -5,993.4%. The company is operating very inefficient. -2
  • The TTM is -5,535.2%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-5,993.4%TTM-5,535.2%-458.2%
TTM-5,535.2%YOY-100,537.2%+95,002.0%
TTM-5,535.2%5Y-22,656.2%+17,121.0%
5Y-22,656.2%10Y-22,656.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,993.4%-299.1%-5,694.3%
TTM-5,535.2%-210.1%-5,325.1%
YOY-100,537.2%-279.7%-100,257.5%
5Y-22,656.2%-459.9%-22,196.3%
10Y-22,656.2%-596.9%-22,059.3%
1.2.2. Operating Ratio

Measures how efficient Inhibikase is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 60.02 means that the operating costs are $60.02 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Inhibikase Therapeutics Inc:

  • The MRQ is 60.016. The company is inefficient in keeping operating costs low. -1
  • The TTM is 55.744. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ60.016TTM55.744+4.272
TTM55.744YOY1,005.389-949.645
TTM55.7445Y227.028-171.284
5Y227.02810Y227.0280.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ60.0162.861+57.155
TTM55.7443.193+52.551
YOY1,005.3893.615+1,001.774
5Y227.0285.560+221.468
10Y227.0287.396+219.632

1.3. Liquidity of Inhibikase Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Inhibikase is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.40 means the company has $6.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Inhibikase Therapeutics Inc:

  • The MRQ is 6.401. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.853. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.401TTM7.853-1.451
TTM7.853YOY8.878-1.025
TTM7.8535Y6.108+1.744
5Y6.10810Y6.1080.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.4013.986+2.415
TTM7.8534.440+3.413
YOY8.8785.552+3.326
5Y6.1086.158-0.050
10Y6.1086.492-0.384
1.3.2. Quick Ratio

Measures if Inhibikase is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Inhibikase to the Biotechnology industry mean.
  • A Quick Ratio of 6.86 means the company can pay off $6.86 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Inhibikase Therapeutics Inc:

  • The MRQ is 6.857. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.474. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.857TTM12.474-5.616
TTM12.474YOY10.086+2.388
TTM12.4745Y7.232+5.242
5Y7.23210Y7.2320.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.8573.638+3.219
TTM12.4744.168+8.306
YOY10.0865.515+4.571
5Y7.2326.012+1.220
10Y7.2326.209+1.023

1.4. Solvency of Inhibikase Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Inhibikase assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Inhibikase to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Inhibikase assets are financed with 16.0% credit (debt) and the remaining percentage (100% - 16.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Inhibikase Therapeutics Inc:

  • The MRQ is 0.160. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.137. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.160TTM0.137+0.023
TTM0.137YOY0.116+0.021
TTM0.1375Y13.931-13.794
5Y13.93110Y13.9310.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1600.335-0.175
TTM0.1370.330-0.193
YOY0.1160.267-0.151
5Y13.9310.367+13.564
10Y13.9310.378+13.553
1.4.2. Debt to Equity Ratio

Measures if Inhibikase is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Inhibikase to the Biotechnology industry mean.
  • A Debt to Equity ratio of 19.1% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Inhibikase Therapeutics Inc:

  • The MRQ is 0.191. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.159. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.191TTM0.159+0.032
TTM0.159YOY0.131+0.028
TTM0.1595Y0.119+0.040
5Y0.11910Y0.1190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1910.376-0.185
TTM0.1590.398-0.239
YOY0.1310.334-0.203
5Y0.1190.429-0.310
10Y0.1190.476-0.357

2. Market Valuation of Inhibikase Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Inhibikase generates.

  • Above 15 is considered overpriced but always compare Inhibikase to the Biotechnology industry mean.
  • A PE ratio of -0.47 means the investor is paying $-0.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Inhibikase Therapeutics Inc:

  • The EOD is -0.774. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.468. Based on the earnings, the company is expensive. -2
  • The TTM is -0.459. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.774MRQ-0.468-0.306
MRQ-0.468TTM-0.459-0.009
TTM-0.459YOY-0.376-0.082
TTM-0.4595Y-0.947+0.489
5Y-0.94710Y-0.9470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.774-2.643+1.869
MRQ-0.468-2.418+1.950
TTM-0.459-2.742+2.283
YOY-0.376-4.123+3.747
5Y-0.947-6.257+5.310
10Y-0.947-6.478+5.531
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Inhibikase Therapeutics Inc:

  • The EOD is -0.867. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.524. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -0.536. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.867MRQ-0.524-0.343
MRQ-0.524TTM-0.536+0.012
TTM-0.536YOY-0.412-0.124
TTM-0.5365Y-1.047+0.512
5Y-1.04710Y-1.0470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.867-3.244+2.377
MRQ-0.524-2.939+2.415
TTM-0.536-3.478+2.942
YOY-0.412-5.592+5.180
5Y-1.047-8.473+7.426
10Y-1.047-8.881+7.834
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Inhibikase is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.57 means the investor is paying $0.57 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Inhibikase Therapeutics Inc:

  • The EOD is 0.947. Based on the equity, the company is cheap. +2
  • The MRQ is 0.573. Based on the equity, the company is cheap. +2
  • The TTM is 0.507. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.947MRQ0.573+0.375
MRQ0.573TTM0.507+0.066
TTM0.507YOY0.221+0.286
TTM0.5075Y0.660-0.153
5Y0.66010Y0.6600.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.9472.124-1.177
MRQ0.5732.041-1.468
TTM0.5072.118-1.611
YOY0.2212.915-2.694
5Y0.6603.682-3.022
10Y0.6604.114-3.454
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Inhibikase Therapeutics Inc.

3.1. Institutions holding Inhibikase Therapeutics Inc

Institutions are holding 10.279% of the shares of Inhibikase Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Vanguard Group Inc1.3262082045-5402-6.1775
2023-12-31Blair William & Co0.97420.0003602688931.504
2023-12-31Geode Capital Management, LLC0.463802869200
2023-12-31Renaissance Technologies Corp0.39480.000124422830051.4824
2023-12-31Redmond Asset Management, LLC0.31750.00819644-1333-6.3546
2023-12-31State Street Corporation0.16301008400
2023-12-31Tower Research Capital LLC0.09570.000159193719169.0455
2023-12-31Royal Bank of Canada0.03230200020000
2023-12-31Morgan Stanley - Brokerage Accounts0.02690166700
2023-12-31Wells Fargo & Co0.00320201-31-13.3621
2023-12-31Bank of America Corp0.001062620
2023-12-31Edgewood Management LLC000-16666-100
2023-09-30Barclays PLC000-11455-100
2023-12-31UBS Group AG000-149-100
2023-12-31JPMorgan Chase & Co000-5-100
2023-12-31Armistice Capital, LLC000-186046-100
Total 3.79860.0085235004-206113-87.7%

3.2. Funds holding Inhibikase Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-01-31Fidelity Extended Market Index0.3440.00022128300
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.2530156499233143.9059
2023-12-31Timber Point Global Allocations Instl0.08890.041550000
2024-01-31Fidelity Nasdaq Composite Index0.05290.0001327200
2024-01-31Fidelity Series Total Market Index0.05230323600
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04230.0001261900
2023-12-31Northern Trust Extended Eq Market Idx0.04230.0001261900
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.03540219300
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.02850176130.1706
2023-12-31SSgA U.S. Extended Market Index Class I0.02290.0001141700
2024-02-29State St US Extended Mkt Indx NL Cl C0.02290.0002141700
2024-01-31Spartan Total Market Index Pool E0.0135083700
2023-12-31SSgA U.S. Total Market Index Strategy0.00660409-9-2.1531
2024-02-29State St US Ttl Mkt Indx SL Cl I0.0065040000
2024-02-29Redmond Small Cap Core0.0050.047830900
2023-12-31NT Ext Eq Mkt Indx Fd DC Lending Tier 50.001107100
Total 1.01810.089662992+9227+14.6%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Inhibikase Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.719-0.409-43%-0.728+1%0.128-663%0.128-663%
Book Value Per Share--2.4283.267-26%5.135-53%2.525-4%2.525-4%
Current Ratio--6.4017.853-18%8.878-28%6.108+5%6.108+5%
Debt To Asset Ratio--0.1600.137+17%0.116+39%13.931-99%13.931-99%
Debt To Equity Ratio--0.1910.159+20%0.131+46%0.119+60%0.119+60%
Dividend Per Share----0%-0%-0%-0%
Eps---0.743-0.781+5%-0.760+2%-0.480-35%-0.480-35%
Free Cash Flow Per Share---0.664-0.728+10%-0.731+10%-0.406-39%-0.406-39%
Free Cash Flow To Equity Per Share---0.664-0.391-41%1.256-153%0.560-218%0.560-218%
Gross Profit Margin--1.0001.0000%1.0000%1.064-6%1.064-6%
Intrinsic Value_10Y_max---59.882--------
Intrinsic Value_10Y_min---50.628--------
Intrinsic Value_1Y_max---3.050--------
Intrinsic Value_1Y_min---2.994--------
Intrinsic Value_3Y_max---11.414--------
Intrinsic Value_3Y_min---10.851--------
Intrinsic Value_5Y_max---22.488--------
Intrinsic Value_5Y_min---20.679--------
Market Cap14228444.000+40%8598929.2009523778.060-10%7118861.710+21%9237418.415-7%9237418.415-7%
Net Profit Margin---57.751-50.798-12%-1003.445+1638%-225.599+291%-225.599+291%
Operating Margin---59.934-55.352-8%-1005.372+1577%-226.562+278%-226.562+278%
Operating Ratio--60.01655.744+8%1005.389-94%227.028-74%227.028-74%
Pb Ratio0.947+40%0.5730.507+13%0.221+159%0.660-13%0.660-13%
Pe Ratio-0.774-65%-0.468-0.459-2%-0.376-20%-0.947+102%-0.947+102%
Price Per Share2.300+40%1.3901.540-10%1.151+21%1.493-7%1.493-7%
Price To Free Cash Flow Ratio-0.867-65%-0.524-0.536+2%-0.412-21%-1.047+100%-1.047+100%
Price To Total Gains Ratio-3.200-65%-1.934-1.388-28%-1.576-19%-2.737+42%-2.737+42%
Quick Ratio--6.85712.474-45%10.086-32%7.232-5%7.232-5%
Return On Assets---0.257-0.206-20%-0.133-48%-1.537+498%-1.537+498%
Return On Equity---0.306-0.240-22%-0.151-51%-0.114-63%-0.114-63%
Total Gains Per Share---0.719-0.409-43%-0.728+1%0.128-663%0.128-663%
Usd Book Value--15017883.00020209671.750-26%31765803.750-53%15620585.526-4%15620585.526-4%
Usd Book Value Change Per Share---0.719-0.409-43%-0.728+1%0.128-663%0.128-663%
Usd Book Value Per Share--2.4283.267-26%5.135-53%2.525-4%2.525-4%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.743-0.781+5%-0.760+2%-0.480-35%-0.480-35%
Usd Free Cash Flow---4105093.000-4503264.500+10%-4522678.000+10%-2514349.947-39%-2514349.947-39%
Usd Free Cash Flow Per Share---0.664-0.728+10%-0.731+10%-0.406-39%-0.406-39%
Usd Free Cash Flow To Equity Per Share---0.664-0.391-41%1.256-153%0.560-218%0.560-218%
Usd Market Cap14228444.000+40%8598929.2009523778.060-10%7118861.710+21%9237418.415-7%9237418.415-7%
Usd Price Per Share2.300+40%1.3901.540-10%1.151+21%1.493-7%1.493-7%
Usd Profit---4595199.000-4635954.750+1%-4694912.500+2%-2928357.368-36%-2928357.368-36%
Usd Revenue--79569.00095985.000-17%15454.500+415%310193.632-74%310193.632-74%
Usd Total Gains Per Share---0.719-0.409-43%-0.728+1%0.128-663%0.128-663%
 EOD+5 -3MRQTTM+8 -25YOY+19 -145Y+9 -2510Y+9 -25

4.2. Fundamental Score

Let's check the fundamental score of Inhibikase Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.774
Price to Book Ratio (EOD)Between0-10.947
Net Profit Margin (MRQ)Greater than0-57.751
Operating Margin (MRQ)Greater than0-59.934
Quick Ratio (MRQ)Greater than16.857
Current Ratio (MRQ)Greater than16.401
Debt to Asset Ratio (MRQ)Less than10.160
Debt to Equity Ratio (MRQ)Less than10.191
Return on Equity (MRQ)Greater than0.15-0.306
Return on Assets (MRQ)Greater than0.05-0.257
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Inhibikase Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.323
Ma 20Greater thanMa 502.232
Ma 50Greater thanMa 1002.363
Ma 100Greater thanMa 2001.759
OpenGreater thanClose2.260
Total2/5 (40.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-09-302022-12-312023-03-312023-06-302023-09-30
Long-term Assets Other  -59530-56530-535171-36444480



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets17,881
Total Liabilities2,863
Total Stockholder Equity15,018
 As reported
Total Liabilities 2,863
Total Stockholder Equity+ 15,018
Total Assets = 17,881

Assets

Total Assets17,881
Total Current Assets17,551
Long-term Assets330
Total Current Assets
Cash And Cash Equivalents 14,861
Short-term Investments 1,970
Other Current Assets 372
Total Current Assets  (as reported)17,551
Total Current Assets  (calculated)17,203
+/- 348
Long-term Assets
Property Plant Equipment 330
Long-term Assets  (as reported)330
Long-term Assets  (calculated)330
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,742
Long-term Liabilities121
Total Stockholder Equity15,018
Total Current Liabilities
Short-term Debt 149
Accounts payable 735
Other Current Liabilities 1,858
Total Current Liabilities  (as reported)2,742
Total Current Liabilities  (calculated)2,742
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt121
Long-term Liabilities  (as reported)121
Long-term Liabilities  (calculated)121
+/-0
Total Stockholder Equity
Common Stock5
Retained Earnings -62,723
Accumulated Other Comprehensive Income 0
Other Stockholders Equity 77,735
Total Stockholder Equity (as reported)15,018
Total Stockholder Equity (calculated)15,018
+/-0
Other
Capital Stock5
Cash and Short Term Investments 16,832
Common Stock Shares Outstanding 5,342
Liabilities and Stockholders Equity 17,881
Net Debt -14,591
Net Invested Capital 15,018
Net Working Capital 14,809
Property Plant and Equipment Gross 354
Short Long Term Debt Total 270



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
0
0
0
38
38
367
1,464
14,783
11,874
49,216
45,869
42,470
38,390
33,992
28,581
24,936
28,163
22,347
17,881
17,88122,34728,16324,93628,58133,99238,39042,47045,86949,21611,87414,7831,4643673838000
   > Total Current Assets 
0
0
0
35
27
30
30
14,783
11,871
49,216
45,869
42,470
38,390
33,949
27,986
24,371
27,629
21,984
17,551
17,55121,98427,62924,37127,98633,94938,39042,47045,86949,21611,87114,78330302735000
       Cash And Cash Equivalents 
0
0
0
18
13
8
16
13,954
9,610
46,837
44,846
40,750
36,611
32,212
5,782
7,189
3,957
1,905
14,861
14,8611,9053,9577,1895,78232,21236,61140,75044,84646,8379,61013,9541681318000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,752
15,862
21,762
19,030
1,970
1,97019,03021,76215,86220,75200000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
333
587
217
110
48
7
14
40
65
80
0
08065401474811021758733300000000
       Other Current Assets 
0
0
0
17
14
23
14
55
1,216
834
541
1,503
1,165
811
506
163
923
544
372
3725449231635068111,1651,5035418341,2165514231417000
   > Long-term Assets 
0
0
0
3
11
336
1,434
829
3
0
0
1,610
0
43
595
565
535
364
330
3303645355655954301,6100038291,434336113000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
0
0
43
595
565
535
364
330
330364535565595430000000000000
       Other Assets 
0
0
0
0
11
336
1,434
-829
3
2,379
45,869
-1,610
1,730
0
0
0
0
0
0
0000001,730-1,61045,8692,3793-8291,434336110000
> Total Liabilities 
0
0
0
4,528
4,739
5,197
6,589
4,998
3,837
2,162
2,708
4,054
4,380
4,490
3,445
3,901
2,842
2,883
2,863
2,8632,8832,8423,9013,4454,4904,3804,0542,7082,1623,8374,9986,5895,1974,7394,528000
   > Total Current Liabilities 
0
0
0
4,253
4,427
4,570
5,914
4,722
3,589
1,913
2,708
4,054
4,380
4,490
3,213
3,695
2,664
2,733
2,742
2,7422,7332,6643,6953,2134,4904,3804,0542,7081,9133,5894,7225,9144,5704,4274,253000
       Short-term Debt 
0
0
0
98
344
43
43
43
995
249
249
249
0
0
142
146
147
148
149
1491481471461420024924924999543434334498000
       Short Long Term Debt 
0
0
0
98
344
43
43
43
995
0
249
249
0
0
0
0
0
0
0
0000000249249099543434334498000
       Accounts payable 
0
0
0
1,002
754
1,094
3,307
1,721
715
897
554
1,090
806
860
781
1,151
959
754
735
7357549591,1517818608061,0905548977151,7213,3071,0947541,002000
       Other Current Liabilities 
0
0
0
1,724
1,858
1,922
607
633
627
624
1,905
2,716
3,574
3,606
2,266
2,398
1,558
1,831
1,858
1,8581,8311,5582,3982,2663,6063,5742,7161,9056246276336071,9221,8581,724000
   > Long-term Liabilities 
0
0
0
275
313
627
675
276
249
249
1,905
2,716
806
3,630
232
205
178
150
121
1211501782052323,6308062,7161,905249249276675627313275000
       Deferred Long Term Liability 
0
0
0
0
11
336
1,434
0
3
0
0
0
0
0
0
0
0
0
0
0000000000301,434336110000
> Total Stockholder Equity
0
0
0
-4,490
-4,702
-4,831
-5,125
9,784
8,037
47,054
43,161
38,416
34,009
29,502
25,136
21,035
25,321
19,464
15,018
15,01819,46425,32121,03525,13629,50234,00938,41643,16147,0548,0379,784-5,125-4,831-4,702-4,490000
   Common Stock
0
0
0
8
9
8
8
10
10
25
25
25
25
25
25
25
31
5
5
55312525252525252510108898000
   Retained Earnings Total Equity0000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
27
105
166
-2
0
0-21661052700000000000000
   Capital Surplus 0000000000000000000
   Treasury Stock0000000000000000000
   Other Stockholders Equity 
0
0
0
7,686
8,020
8,314
8,690
24,806
25,695
67,334
67,912
68,208
68,442
68,575
68,677
68,777
77,474
77,588
77,735
77,73577,58877,47468,77768,67768,57568,44268,20867,91267,33425,69524,8068,6908,3148,0207,686000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-20,021
Operating Income-20,021-20,021
 
Operating Expense (+$)
Research Development13,670
Selling General Administrative6,676
Selling And Marketing Expenses-
Operating Expense20,02120,345
 
Net Interest Income (+$)
Interest Income891
Interest Expense--
Other Finance Cost-0
Net Interest Income891
 
Pretax Income (+$)
Operating Income-20,021
Net Interest Income891
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-19,130-20,021
EBIT - interestExpense = 0
-19,130
-19,130
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--19,130
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-19,130
Tax Provision--
Net Income From Continuing Ops-19,130-19,130
Net Income-19,130
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--891
 

Technical Analysis of Inhibikase
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Inhibikase. The general trend of Inhibikase is BULLISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Inhibikase's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (42.9%) Bearish trend (-42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Inhibikase Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.49 < 2.49 < 3.12.

The bearish price targets are: 1.8 > 1.53 > 1.45.

Tweet this
Inhibikase Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Inhibikase Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 10/14.
The longshort score for the Moving Averages is 6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Inhibikase Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Inhibikase Therapeutics Inc. The current macd is -0.01931101.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Inhibikase price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Inhibikase. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Inhibikase price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Inhibikase Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartInhibikase Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Inhibikase Therapeutics Inc. The current adx is 15.25.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Inhibikase shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Inhibikase Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Inhibikase Therapeutics Inc. The current sar is 1.83415808.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Inhibikase Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Inhibikase Therapeutics Inc. The current rsi is 53.32. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Inhibikase Therapeutics Inc Daily Relative Strength Index (RSI) ChartInhibikase Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Inhibikase Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Inhibikase price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Inhibikase Therapeutics Inc Daily Stochastic Oscillator ChartInhibikase Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Inhibikase Therapeutics Inc. The current cci is 41.18.

Inhibikase Therapeutics Inc Daily Commodity Channel Index (CCI) ChartInhibikase Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Inhibikase Therapeutics Inc. The current cmo is 14.04.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Inhibikase Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartInhibikase Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Inhibikase Therapeutics Inc. The current willr is -27.53623188.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Inhibikase is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Inhibikase Therapeutics Inc Daily Williams %R ChartInhibikase Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Inhibikase Therapeutics Inc. The current atr is 0.2073372.

Inhibikase Therapeutics Inc Daily Average True Range (ATR) ChartInhibikase Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Inhibikase Therapeutics Inc. The current obv is -10,061,778.

Inhibikase Therapeutics Inc Daily On-Balance Volume (OBV) ChartInhibikase Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Inhibikase Therapeutics Inc. The current mfi is 40.06.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Inhibikase Therapeutics Inc Daily Money Flow Index (MFI) ChartInhibikase Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Inhibikase Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-16ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-13CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Inhibikase Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Inhibikase Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.323
Ma 20Greater thanMa 502.232
Ma 50Greater thanMa 1002.363
Ma 100Greater thanMa 2001.759
OpenGreater thanClose2.260
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Inhibikase with someone you think should read this too:
  • Are you bullish or bearish on Inhibikase? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Inhibikase? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Inhibikase Therapeutics Inc

I send you an email if I find something interesting about Inhibikase Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Inhibikase Therapeutics Inc.

Receive notifications about Inhibikase Therapeutics Inc in your mailbox!